Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.19
Equity-to-Asset	0.47
Debt-to-Equity	0.54
Debt-to-EBITDA	2.15
Interest Coverage	8.27
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.93	Distress Grey Safe
Beneish M-Score	-3.03	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	11.8
	3-Year EBITDA Growth Rate	-3.8
	3-Year EPS without NRI Growth Rate	11
	3-Year FCF Growth Rate	36.2
	3-Year Book Growth Rate	4.5
	Future 3-5Y EPS without NRI Growth Rate	3.4
	Future 3-5Y Total Revenue Growth Rate	4.3

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	66.75
	9-Day RSI	55.34
	14-Day RSI	50.75
	6-1 Month Momentum %	-1.77
	12-1 Month Momentum %	8.82

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.57
	Quick Ratio	0.9
	Cash Ratio	0.17
	Days Inventory	209.38
	Days Sales Outstanding	103.32
	Days Payable	91.46

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	3.14
	Dividend Payout Ratio	0.28
	3-Year Dividend Growth Rate	12.7
	Forward Dividend Yield %	3.14
	5-Year Yield-on-Cost %	5.46
	3-Year Average Share Buyback Ratio	1.4
	Shareholder Yield %	7.34

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	48.35
	Operating Margin %	21.01
	Net Margin %	6.61
	FCF Margin %	18.51
	ROE %	8.64
	ROA %	4.09
	ROIC %	10.54
	ROC (Joel Greenblatt) %	18.52
	ROCE %	10.35
	Years of Profitability over Past 10-Year	9

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	26.77
	Forward PE Ratio	11.38
	PE Ratio without NRI	10.29
	Shiller PE Ratio	25.18
	Price-to-Owner-Earnings	15.46
	PEG Ratio	3.22
	PS Ratio	1.76
	PB Ratio	2.29
	Price-to-Tangible-Book	4.72
	Price-to-Free-Cash-Flow	9.5
	Price-to-Operating-Cash-Flow	6.87
	EV-to-EBIT	17.39
	EV-to-Forward-EBIT	11.2
	EV-to-EBITDA	11.16
	EV-to-Forward-EBITDA	8.01
	EV-to-Revenue	2.15
	EV-to-Forward-Revenue	2.09
	EV-to-FCF	11.31
	Price-to-Projected-FCF	0.92
	Price-to-DCF (Earnings Based)	0.8
	Price-to-DCF (FCF Based)	0.7
	Price-to-Median-PS-Value	0.6
	Price-to-Graham-Number	1.49
	Earnings Yield (Greenblatt) %	5.76
	FCF Yield %	10.28
	Forward Rate of Return (Yacktman) %	9.76

Financials (Next Earnings Date:2024-08-08 Est.)

Annual Quarterly TTM

FRA:H5P's 30-Y Financials

AAPL

Income Statement Breakdown

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Hikma Pharmaceuticals PLC Executives

Details

GF Value: €24.7

FRA:H5P

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Medium warning signs with H5P. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	2,644.937
	EPS (TTM) (€)	0.783
	Beta	1.06
	Volatility %	25.62
	14-Day RSI	50.75
	14-Day ATR (€)	0.35603
	20-Day SMA (€)	21.41
	12-1 Month Momentum %	8.82
	52-Week Range (€)	19.7 - 25.6
	Shares Outstanding (Mil)	221.89

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Hikma Pharmaceuticals PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Hikma Pharmaceuticals PLC Stock Events

Financials Calendars

	Event	Date	Price(€)
No Event Data

Hikma Pharmaceuticals PLC Frequently Asked Questions

What is Hikma Pharmaceuticals PLC(FRA:H5P)'s stock price today?

The current price of FRA:H5P is €21.60. The 52 week high of FRA:H5P is €25.60 and 52 week low is €19.70.

When is next earnings date of Hikma Pharmaceuticals PLC(FRA:H5P)?

The next earnings date of Hikma Pharmaceuticals PLC(FRA:H5P) is 2024-08-08 Est..

Does Hikma Pharmaceuticals PLC(FRA:H5P) pay dividends? If so, how much?

The Dividend Yield % of Hikma Pharmaceuticals PLC(FRA:H5P) is 3.14% (As of Today), Highest Dividend Payout Ratio of Hikma Pharmaceuticals PLC(FRA:H5P) was 0.32. The lowest was 0.13. And the median was 0.27. The Forward Dividend Yield % of Hikma Pharmaceuticals PLC(FRA:H5P) is 3.14%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.